## International prospective register of systematic reviews





# Systematic review

## 1. \* Review title.

Give the title of the review in English

Perceptions of risk in pregnancy with chronic disease: A systematic review and thematic synthesis

## 2. Original language title.

For reviews in languages other than English, give the title in the original language. This will be displayed with the English language title.

### 3. \* Anticipated or actual start date.

Give the date the systematic review started or is expected to start.

#### 15/04/2019

## 4. \* Anticipated completion date.

Give the date by which the review is expected to be completed.

#### 01/04/2020

## 5. \* Stage of review at time of this submission.

Tick the boxes to show which review tasks have been started and which have been completed. Update this field each time any amendments are made to a published record.

Reviews that have started data extraction (at the time of initial submission) are not eligible for inclusion in PROSPERO. If there is later evidence that incorrect status and/or completion date has been supplied, the published PROSPERO record will be marked as retracted.

This field uses answers to initial screening questions. It cannot be edited until after registration.

#### The review has not yet started: No

Review stage	Started	Completed
Preliminary searches	Yes	Yes
Piloting of the study selection process	Yes	Yes
Formal screening of search results against eligibility criteria	Yes	Yes
Data extraction	Yes	Yes
Risk of bias (quality) assessment	Yes	Yes
Data analysis	Yes	Yes

## International prospective register of systematic reviews



Provide any other relevant information about the stage of the review here.

The review has been completed and is being submitted for publication.

The review has been completed and is being submitted for publication.

#### 6. \* Named contact.

The named contact is the guarantor for the accuracy of the information in the register record. This may be any member of the review team.

Elizabeth R Ralston

Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence:

Miss Ralston

#### 7. \* Named contact email.

Give the electronic email address of the named contact.

elizabeth.ralston@kcl.ac.uk

#### 8. Named contact address

Give the full institutional/organisational postal address for the named contact.

3rd Floor, Addison House, Kings College London, SE1 1UL

### 9. Named contact phone number.

Give the telephone number for the named contact, including international dialling code.

### 10. \* Organisational affiliation of the review.

Full title of the organisational affiliations for this review and website address if available. This field may be completed as 'None' if the review is not affiliated to any organisation.

King's College London

Organisation web address:

https://www.kcl.ac.uk/

## 11. \* Review team members and their organisational affiliations.

Give the personal details and the organisational affiliations of each member of the review team. Affiliation refers to groups or organisations to which review team members belong. **NOTE: email and country now MUST be entered for each person, unless you are amending a published record.** 

Miss Elizabeth Ralston. King's College London

Dr Kate Bramham. King's College London

Dr Priscilla Smith. Guy's and St Thomas' NHS Foundation Trust

Dr Joseph Chilcot. King's College London

Mr Sergio Silverio. King's College London

## 12. \* Funding sources/sponsors.

## International prospective register of systematic reviews



Details of the individuals, organizations, groups, companies or other legal entities who have funded or sponsored the review.

Studentship funding to Elizabeth Ralston from King's Medical Research Trust, Joint Research Committee Grant number(s)

State the funder, grant or award number and the date of award

#### 13. \* Conflicts of interest.

List actual or perceived conflicts of interest (financial or academic).

None

### 14. Collaborators.

Give the name and affiliation of any individuals or organisations who are working on the review but who are not listed as review team members. **NOTE: email and country must be completed for each person, unless you are amending a published record.** 

## 15. \* Review question.

State the review question(s) clearly and precisely. It may be appropriate to break very broad questions down into a series of related more specific questions. Questions may be framed or refined using PI(E)COS or similar where relevant.

The objective is to systematically review the qualitative literature to describe risk perceptions of pregnancy in women with chronic diseases.

#### 16. \* Searches.

State the sources that will be searched (e.g. Medline). Give the search dates, and any restrictions (e.g. language or publication date). Do NOT enter the full search strategy (it may be provided as a link or attachment below.)

Therforetowing tenestrestric attentate for the content of the cont

- o MEDLINE (1946 to 2020)
- o Scopus (1996 to 2020)
- o PsycINFO (1960 to 2020)
- o EMBASE (1974 to 2020)
- o Global Health (1973 to 2020)
- o Web of Science (1900 to 2020)
- o CINAHL (Cumulative Index to Nursing and Allied Health Literature 1981 to 2020)

To reduce publication bias, grey literature will also be searched. Grey literature will be searched using the following sources:

- o OpenGrey
- o British Library Electronic Theses Online Service (EThOS)
- o Dart European (Digital Access to Research Theses Europe)

### International prospective register of systematic reviews



### o OpenAIRE

## 17. URL to search strategy.

Upload a file with your search strategy, or an example of a search strategy for a specific database, (including the keywords) in pdf or word format. In doing so you are consenting to the file being made publicly accessible. Or provide a URL or link to the strategy. Do NOT provide links to your search **results**.

#### https://www.crd.york.ac.uk/PROSPEROFILES/132367 STRATEGY 20190415.pdf

Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.

Do not make this file publicly available until the review is complete

## 18. \* Condition or domain being studied.

Give a short description of the disease, condition or healthcare domain being studied in your systematic review.

Risk perception is an individual's subjective appraisal of potential harm (Brewer et al., 2007). This subjective appraisal of risk is composed of three dimensions; the perceived severity of the potential harm, the perceived likelihood of the harm occurring and the perceived susceptibility of the individual to the harm (Brewer et al., 2007; Darker 2013). This review is exploring women's risk perceptions in pregnancy with chronic disease.

## 19. \* Participants/population.

Specify the participants or populations being studied in the review. The preferred format includes details of both inclusion and exclusion criteria.

Women who are currently pregnant (not restrictive to gestational age), experienced pregnancy or planning a pregnancy (including those attending pre-pregnancy counselling), who have a diagnosis of a chronic medical condition or long-term condition prior to pregnancy. This includes; chronic kidney disease, chronic lung disease, chronic rheumatological disease, diabetes, obesity, hypertension, epilepsy, coronary heart disease.

## 20. \* Intervention(s), exposure(s).

Give full and clear descriptions or definitions of the interventions or the exposures to be reviewed. The preferred format includes details of both inclusion and exclusion criteria.

Not applicable.

#### 21. \* Comparator(s)/control.

Where relevant, give details of the alternatives against which the intervention/exposure will be compared (e.g. another intervention or a non-exposed control group). The preferred format includes details of both inclusion and exclusion criteria.

Not applicable.

## 22. \* Types of study to be included.

Give details of the study designs (e.g. RCT) that are eligible for inclusion in the review. The preferred format includes both inclusion and exclusion criteria. If there are no restrictions on the types of study, this should be stated.

## International prospective register of systematic reviews



Qualitative study designs are eligible for the review. Quantitative (including; cross-sectional, cohort, randomised control trials, pre/post intervention, observational, case-control), meta-analysis and systematic reviews will be excluded. There are no time restrictions on publication.

Papers must be published in English and fully accessible. If only the abstract can be reviewed it will be excluded. Previously restricting to published in English would have introduced a language bias, although as English is now regarded as the universal language of science (Morrisson et al., 2012), the extent of introducing a language bias is reduced (Higgins and Green, 2011).

#### 23. Context.

Give summary details of the setting or other relevant characteristics, which help define the inclusion or exclusion criteria.

## 24. \* Main outcome(s).

Give the pre-specified main (most important) outcomes of the review, including details of how the outcome is defined and measured and when these measurement are made, if these are part of the review inclusion criteria.

The primary outcome of this review is describing women's risk perceptions in pregnancy with chronic conditions. Data items regarding women's risk perceptions will be extracted. Qualitative responses, including women's risk appraisal and perceptions of maternal and neonatal risk.

#### Measures of effect

Please specify the effect measure(s) for you main outcome(s) e.g. relative risks, odds ratios, risk difference, and/or 'number needed to treat.

Not applicable.

## 25. \* Additional outcome(s).

List the pre-specified additional outcomes of the review, with a similar level of detail to that required for main outcomes. Where there are no additional outcomes please state 'None' or 'Not applicable' as appropriate to the review

None.

### Measures of effect

Please specify the effect measure(s) for you additional outcome(s) e.g. relative risks, odds ratios, risk difference, and/or 'number needed to treat.

Not applicable.

## 26. \* Data extraction (selection and coding).

Describe how studies will be selected for inclusion. State what data will be extracted or obtained. State how this will be done and recorded.

The selection process will be guided by PRISMA statement. The data will initially be identified from the search and extracted, with duplicates removed. Titles and abstracts will be screened for eligibility. Two independent reviewers (ER & PS) will assess the full texts with the inclusion and exclusion criteria. The discrepancies will be discussed, if no consensus is agreed a third individual will be consulted.

## International prospective register of systematic reviews



## 27. \* Risk of bias (quality) assessment.

State which characteristics of the studies will be assessed and/or any formal risk of bias/quality assessment tools that will be used.

The papers included in the final review will be assessed for within study-risk of bias. Critical Appraisal Skills Program Qualitative List will be used to assess the qualitative research. Two researchers (ER and PS) will independently assess the quality of the publications.

### 28. \* Strategy for data synthesis.

Describe the methods you plan to use to synthesise data. This **must not be generic text** but should be **specific to your review** and describe how the proposed approach will be applied to your data. If meta-analysis is planned, describe the models to be used, methods to explore statistical heterogeneity, and software package to be used.

A thematic synthesis will be provided with the information presented in the text and tables to summarise and explain the findings and characteristics of the included studies. The narrative synthesis will follow guidance from Thomas and Harden (2008).

## 29. \* Analysis of subgroups or subsets.

State any planned investigation of 'subgroups'. Be clear and specific about which type of study or participant will be included in each group or covariate investigated. State the planned analytic approach.

There are no plans for analysis of subgroups.

## 30. \* Type and method of review.

Select the type of review, review method and health area from the lists below.

Type of review

Cost effectiveness

No

Diagnostic

No

**Epidemiologic** 

Νo

Individual patient data (IPD) meta-analysis

No

Intervention

No

Meta-analysis

No

Methodology

No

Narrative synthesis

Yes

Network meta-analysis

No

## International prospective register of systematic reviews



Pre-clinical

No

Prevention

No

Prognostic

No

Prospective meta-analysis (PMA)

No

Review of reviews

No

Service delivery

No

Synthesis of qualitative studies

Yes

Systematic review

Yes

Other

No

## Health area of the review

Alcohol/substance misuse/abuse

No

Blood and immune system

No

Cancer

No

Cardiovascular

No

Care of the elderly

No

Child health

No

Complementary therapies

No

COVID-19

No

Crime and justice

No

Dental

No

Digestive system

No

Ear, nose and throat

## International prospective register of systematic reviews



No

Education

No

Endocrine and metabolic disorders

Nc

Eye disorders

No

General interest

No

Genetics

No

Health inequalities/health equity

No

Infections and infestations

No

International development

No

Mental health and behavioural conditions

No

Musculoskeletal

No

Neurological

No

Nursing

Nο

Obstetrics and gynaecology

No

Oral health

No

Palliative care

No

Perioperative care

Nο

Physiotherapy

No

Pregnancy and childbirth

Yes

Public health (including social determinants of health)

No

Rehabilitation

No

Respiratory disorders

No

### International prospective register of systematic reviews



Service delivery

No

Skin disorders

No

Social care

No

Surgery

No

**Tropical Medicine** 

No

Urological

No

Wounds, injuries and accidents

No

Violence and abuse

No

## 31. Language.

Select each language individually to add it to the list below, use the bin icon to remove any added in error. English

There is an English language summary.

## 32. \* Country.

Select the country in which the review is being carried out. For multi-national collaborations select all the countries involved.

**England** 

## 33. Other registration details.

Name any other organisation where the systematic review title or protocol is registered (e.g. Campbell, or The Joanna Briggs Institute) together with any unique identification number assigned by them. If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here. If none, leave blank.

## 34. Reference and/or URL for published protocol.

If the protocol for this review is published provide details (authors, title and journal details, preferably in Vancouver format)

Add web link to the published protocol.

Or, upload your published protocol here in pdf format. Note that the upload will be publicly accessible.

#### No I do not make this file publicly available until the review is complete

Please note that the information required in the PROSPERO registration form must be completed in full even if access to a protocol is given.

### 35. Dissemination plans.

Do you intend to publish the review on completion?

### International prospective register of systematic reviews



#### Yes

Give brief details of plans for communicating review findings.?

The systematic review is planned to be published on completion. As well as the abstract being submitted for a poster presentation at a conference within the United Kingdom.

## 36. Keywords.

Give words or phrases that best describe the review. Separate keywords with a semicolon or new line. Keywords help PROSPERO users find your review (keywords do not appear in the public record but are included in searches). Be as specific and precise as possible. Avoid acronyms and abbreviations unless these are in wide use.

Risk perception; pregnancy; chronic illness; health beliefs

## 37. Details of any existing review of the same topic by the same authors.

If you are registering an update of an existing review give details of the earlier versions and include a full bibliographic reference, if available.

#### 38. \* Current review status.

Update review status when the review is completed and when it is published. New registrations must be ongoing so this field is not editable for initial submission.

Please provide anticipated publication date

Review\_Completed\_not\_published

## 39. Any additional information.

Provide any other information relevant to the registration of this review.

## 40. Details of final report/publication(s) or preprints if available.

Leave empty until publication details are available OR you have a link to a preprint (NOTE: this field is not editable for initial submission). List authors, title and journal details preferably in Vancouver format.

Give the link to the published review or preprint.

Page: 10 / 10